Patents Assigned to Codexis, Inc.
  • Patent number: 12018295
    Abstract: The present invention provides engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The invention also provides methods for use of the compositions comprising the engineered DNA polymerase polypeptides for diagnostic and other purposes.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: June 25, 2024
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Vesna Mitchell, Jovana Nazor, Donald S. Baskerville, Nikki Dellas, David Elgart, Jonathan Vroom, Sandy M. Gomes, Nandhitha Subramanian, Ericka Bermudez
  • Patent number: 12012620
    Abstract: The present invention provides engineered peroxidase enzymes, polypeptides having peroxidase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing peroxidase enzymes are also provided. The present invention further provides compositions comprising the peroxidase enzymes and methods of using the engineered peroxidase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: June 18, 2024
    Assignee: Codexis, Inc.
    Inventors: Da Duan, Auric Anthony Sowell-Kantz, Aksiniya Lyubenova Petkova, Jovana Nazor, Nandhitha Subramanian, Oscar Alvizo
  • Patent number: 12012618
    Abstract: The present invention provides engineered galactose oxidase (GOase) enzymes, polypeptides having GOase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GOase enzymes are also provided. The present invention further provides compositions comprising the GOase enzymes and methods of using the engineered GOase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: June 18, 2024
    Assignee: Codexis, Inc.
    Inventors: Christopher Michael Micklitsch, Oscar Alvizo, Jovana Nazor, Harvinder Chagger Maniar, Mikayla Jianghongxia Krawczyk, Margie Tabuga Borra-Garske, Nandhitha Subramanian, Anna Fryszkowska, Nicholas M. Marshall, Agustina Rodriguez-Granillo, Deeptak Verma, Dewan Andrews
  • Publication number: 20240182876
    Abstract: The present invention provides engineered terminal deoxynucleotidyl transferase (TdT) polypeptides useful in template-independent polynucleotide synthesis, as well as compositions, methods of utilizing these engineered polypeptides, and polynucleotides encoding the engineered terminal deoxynucleotidyl transferases.
    Type: Application
    Filed: October 12, 2023
    Publication date: June 6, 2024
    Applicant: Codexis, Inc.
    Inventors: David Entwistle, Stephanie Forget, Michelle Li, Niusha Mahmoodi, Ryan Reeves, Ljubica Vojcic, Jonathan Vroom, David Watts, Leland Ken Wong
  • Patent number: 11987818
    Abstract: The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: May 21, 2024
    Assignee: Codexis, Inc.
    Inventors: Margie Tabuga Borra-Garske, Oscar Alvizo, Melissa Ann Mayo, Stephan Jenne, Auric Anthony Sowell-Kantz, Carmela Molinaro
  • Patent number: 11970722
    Abstract: The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: April 30, 2024
    Assignee: Codexis, Inc.
    Inventors: William Casey Hallows, Rachel Cathleen Botham, Yu Zhu, Chinping Chng, Nikki Dellas, Gjalt W. Huisman, Moulay Hicham Alaoui Ismaili, David William Homan, Adam P. Silverman, Jonathan Vroom, Jessica P. Lao
  • Patent number: 11965192
    Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: April 23, 2024
    Assignee: Codexis, Inc.
    Inventors: Jovana Nazor, Vesna Mitchell, David Elgart, Katrina W. Lexa, Nikki Dellas, Robert Kevin Orr, Oscar Alvizo, Ravi David Garcia, Judy Victoria Antonio Viduya, Courtney Dianne Moffett
  • Patent number: 11965194
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize chiral compounds.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: April 23, 2024
    Assignee: Codexis, Inc.
    Inventors: Jack S. Liang, Stephan Jenne, Emily Mundorff, Rama Voladri, James J. Lalonde, Gjalt W. Huisman
  • Patent number: 11959108
    Abstract: The present invention provides engineered protease polypeptides and compositions thereof. The engineered protease polypeptides have been optimized to provide improved activity, improved thermostability, protease stability, autolytic stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered protease polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered protease polypeptides, as well as methods for making the engineered polynucleotides and protease polypeptides.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: April 16, 2024
    Assignees: Codexis, Inc., Societe des Produits Nestle S.A.
    Inventors: Chinping Chng, Nikki Dellas, Ravi David Garcia, Moulay Hicham Alaoui Ismaili, Kristen Jean Vallieu, Kerryn McCluskie
  • Patent number: 11926857
    Abstract: The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: March 12, 2024
    Assignee: Codexis, Inc.
    Inventors: Lynne Gilson, Steven J. Collier, Joly Sukumaran, Wan Lin Yeo, Oscar Alvizo, Ee Ling Teo, Robert J. Wilson, Junye Xu
  • Patent number: 11913036
    Abstract: The present invention provides engineered acetate kinase (AcK) enzymes, polypeptides having AcK activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing AcK enzymes are also provided. The present invention further provides compositions comprising the AcK enzymes and methods of using the engineered AcK enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: February 27, 2024
    Assignee: Codexis, Inc.
    Inventors: Margie Tabuga Borra-Garske, Oscar Alvizo, Lillian Jasmine Miller, Aksiniya Lyubenova Petkova
  • Patent number: 11913045
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: February 27, 2024
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 11913037
    Abstract: The present invention provides engineered adenylate kinase (AdK) enzymes, polypeptides having AdK activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing AdK enzymes are also provided. The present invention further provides compositions comprising the AdK enzymes and methods of using the engineered AdK enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: February 27, 2024
    Assignee: Codexis, Inc.
    Inventors: Da Duan, Auric Anthony Sowell-Kantz, Aksiniya Lyubenova Petkova, Oscar Alvizo
  • Patent number: 11898174
    Abstract: The present invention provides engineered uridine phosphorylase (UP) enzymes, polypeptides having UP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing UP enzymes are also provided. The present invention further provides compositions comprising the UP enzymes and methods of using the engineered UP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: February 13, 2024
    Assignee: Codexis, Inc.
    Inventors: Jonathan Vroom, Jessica Anna Hurtak, Anders Matthew Knight
  • Patent number: 11845968
    Abstract: The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: December 19, 2023
    Assignee: Codexis, Inc.
    Inventors: Da Duan, Oscar Alvizo, Jovana Nazor, Harvinder Chagger Maniar, James Nicholas Riggins, Jonathan Vroom, Santhosh Sivaramakrishnan, Hao Yang, Anna Fryszkowska, Mark A. Huffman, Joshua N. Kolev, Iman Farasat, Agustina Rodriguez-Granillo, Deeptak Verma
  • Patent number: 11807874
    Abstract: The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: November 7, 2023
    Assignee: Codexis, Inc.
    Inventors: Robert Osborne, Vesna Mitchell, Khin Yu Naing Htwe, Xiyun Zhang, Erika M. Milczek, Jeffrey C. Moore
  • Patent number: 11802274
    Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: October 31, 2023
    Assignee: Codexis, Inc.
    Inventors: Oscar Alvizo, Melissa Ann Mayo, Jeffrey C. Moore
  • Patent number: 11795445
    Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: October 24, 2023
    Assignee: Codexis, Inc.
    Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant S. Murphy, Nicholas Marshall, Jay Russell, Keith A. Canada
  • Patent number: 11788071
    Abstract: The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: October 17, 2023
    Assignee: Codexis, Inc.
    Inventors: Scott J. Novick, Nikki Dellas
  • Patent number: 11767519
    Abstract: The present invention provides engineered amylase polypeptides and compositions thereof. The engineered amylase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The invention also relates to the use of the compositions comprising the engineered amylase polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered amylase polypeptides, as well as methods for making the engineered polynucleotides and amylase polypeptides.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: September 26, 2023
    Assignees: Codexis, Inc., Societe des Produits Nestle S.A.
    Inventors: Chinping Chng, Nikki Dellas, Da Duan, Ravi David Garcia, Harvinder Chagger Maniar